Answers are grounded in this paper and cite their sources.
PURPOSE: To compare adherence rates, measured by the proportion of days covered (PDC), in patients with phenylketonuria (PKU) prescribed sapropterin utilizing an integrated health-system specialty pharmacy (HSSP) vs a nonintegrated specialty pharmacy. METHODS: This retrospective, observational study evaluated sapropterin fills between January and December 2024. Patient demographics, sapropterin prescription information, fill data, and phenylalanine (Phe) levels were collected. Data were analyzed by Wilcoxon rank-sum test or by χ2 analysis or Fisher's exact test, as appropriate. A logistic regression model predicting likelihood of adherence (PDC of ≥80%) used forward/backward elimination of covariates. RESULTS: Fifty-four patients were included (median age, 15 years; interquartile range [IQR], 9.25-28.5 years; 52% female), of whom 17 utilized the integrated HSSP and 37 used a nonintegrated specialty pharmacy. The median PDC was 0.97 (IQR, 0.95-0.99) for the HSSP group and 0.91 (IQR, 0.75-0.99) for the nonintegrated specialty pharmacy group, with a between-group difference of 0.07 (95% confidence interval [CI], -0.05 to 0.19; P = 0.23). However, achievement of high (≥90%) or threshold (≥80%) adherence was more likely in the HSSP group, with proportions of 88.2% vs 51.4% (P = 0.01) and 88.2% vs 67.6% (P = 0.18), respectively. The Phe concentration was numerically lower for the group with a PDC of ≥80% than for the group with a PDC of <80%, with mean (SD) levels of 8.6 (4.5) mg/dL and 11.0 (6.3) mg/dL, respectively (P = 0.32). Integrated HSSP use was associated with nearly 5-fold-greater odds of achieving threshold adherence (adjusted odds ratio, 4.98; 95% CI, 0.75-33.3; P = 0.096), although the difference was not statistically significant. CONCLUSION: Patients using the HSSP were more likely to achieve high adherence, although differences in overall median adherence rates were not statistically significant. These findings highlight the potential value of integrated pharmacy models and support further investigation into optimizing clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Riedy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: